Decision Resources offers US under-treatment detector

The northeastern US states of Massachusetts, Maine and Vermont have the highest percentages of dyslipidemia patients who have prescription drug coverage but are currently untreated, according to a new analytics tool from Decision Resources.

The new product from Decision Resources entitled PatientFinder: Dyslipidemia reveals that Massachusetts ranks 27th, Maine 36th and Vermont 40th out of the 50 US states in the percentage of their prevalent population that are currently receiving drug therapy for dyslipidemia. As a result of this under-treatment is that a significant opportunity remains for market growth in each of these New England states. Decision Resouces argues that this type of information is invaluable to pharmaceutical firms which find it challenging to pinpoint the areas of greatest need for their drugs.

With the type of information included in PatientFinder, drugmakers can identify the local markets that offer the greatest opportunity for their branded product. Companies can locate areas that are underserviced and determine if they should increase direct-to-consumer advertising, as well as partner with local managed-care organizations to raise awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.